Yesterday’s results looked solid. Today Shore Capital goes further, arguing GSK has effectively delivered its medium-term ...

Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a ...

GSK plc GSK reported fourth-quarter 2025 core earnings of 68 cents per American depositary share (ADS), which beat the Zacks ...

GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...

GSK plc reports fourth-quarter earnings Wednesday, marking the first results under new Chief Executive Luke Miels as the ...

Shares of GSK PLC GSK dropped 1.77% to £21.59 Monday, on what proved to be an all-around positive trading session for the stock market, with the FTSE 100 Index UKX rising 0.16% to 10,386.23. GSK PLC ...

GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older: London, UK Wednesday, February 11, 2026, 09:00 Hrs [IST] GSK plc announced ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

(GSK) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit The Law Offices of Frank R. Cruz reminds investors of the upcoming April 7, 2025 ...

The analyst based the rating on factors related to the company’s Blenrep drug, stating that the FDA briefing documents highlighted considerable concerns regarding its ocular toxicity and dosing.

(Alliance News) - GSK PLC on Tuesday said its respiratory syncytial virus vaccine Arexvy has been accepted for review by China's Center for Drug Evaluation for adults aged 60 and over. The ...